PALO ALTO, CA, USA I April 15, 2025 I Evommune, Inc., a clinical stage biotechnology company discovering and developing new ways to treat immune-mediated ...

Late-breaking oral presentation to include full Phase 1b results for TX45 in the Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”) cohortWATERTOWN, Mass., ...

Capital will Support Continued Development of First-in-Class GPR35 Inhibitor Program for the Treatment of Ulcerative Colitis Utilizing Biomarker-D ...

Dr Morgan Li, Dr Alexandre Siqueira, Dr Sarah Piper, Dr Marcus Giansiracusa and Dr Laura Williams. Images supplied.Five ...

Cysteinyl leukotrienes (CysLTs) are potent bronchoconstrictors, playing pivotal roles in inflammatory diseases. These lipid mediators exert their effects by activating two G protein-coupled receptors, ...

Palatin Technologies, Inc. , a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that ...

A new study in Engineering explores the role of astrocytic G protein-coupled receptors in drug addiction. It shows that these receptors, including ...

At the recent AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Disease (PD), Cerevance announced that solengepras, a first-in-class G-protein coupled receptor 6 (GPR6) antagonist in ...

A new study shows how common gut bacteria can metabolize certain oral medications that target cellular receptors called GPCRs, potentially rendering these important drugs less effective.

The proteins – large molecules that play many important roles in the body – help to relay information and are known GPCRs, or ...

Several studies have been conducted, but questions remain about where such therapies will fit into multiple myeloma treatment strategies.